trial

An Open-Label, Single-Arm Clinical Trial Evaluating the Safety and Efficacy of Amisulpride in Treating Patients With Schizophrenia and Schizoaffective Disorder Who Have Treatment-Resistant Positive Symptoms

NCTId NCT05956600
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Withdrawn
Enrollment 0 (actual)
Sponsored by University of California Riverside at C.I. Trials, Inc.-Inland Empire
Primary completion 2025-11
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Withdrawn
Enrollment
0 (actual)
Study type
Interventional
Allocation
Na
Model
Single Group
Masking
None
Start
2023-11
Primary completion
2025-11
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
Amisulpride

Sponsors

University of California Riverside at C.I. Trials, Inc.-Inland EmpireLead Sponsor
PoloMar Health LLCCollaborator

Sites

0 total

Facts & assertions

4 sourced
Enrollment
0
Phase
NA
Primary Completion Date
2025-11
Status
WITHDRAWN
relationships
The graph out of here
drug
Amisulpride
drug
lead_sponsor
University of California Riverside at C.I. Trials, Inc.-Inland Empire
company
collaborator
PoloMar Health LLC
company
indication
Schizophrenia, Treatment-Resistant
indication
Schizophrenia
indication
Schizophrenia, Treatment-Resistant
indication